Remedium raises $10m for adjustable gene therapy
Lilly joins Series A backing a platform designed to turn adipocytes into long-term, adjustable producers of therapeutic proteins. Remedium Bio has announced the initial close of a planned $10 million Series A financing, bringing new capital to its effort to develop durable, adjustable gene therapies
<p>Lilly joins Series A backing a platform designed to turn adipocytes into long-term, adjustable producers of therapeutic proteins. Remedium Bio has announced the initial close of a planned $10 million Series A financing, bringing new capital to its effort to develop durable, adjustable gene therapies</p>